Cutting edge translational research in tumor vaccine immunotherapies
Email us at: email@example.com
We recently acquired the rights to a Newcastle Disease Virus sub-type specifically attenuated to diminish its infectivity of poultry and wildlife yet which continues to be lytic to tumor cells and immuno-stimultory to the patient's T-cells.
Our vaccine will include specifically modified allogeneic tumor cells grown in culture, infected with our NDV, and the resultant solution (PIV-001) and fractured tumor cells will be purified and certified for use in human patients with solid tumors, specifically lung cancer (NSCLC).
We also have underway a study in human subjects with common and plantar warts the use of well-defined skin test antigens in combonation as an injectable immuno-stimulatory vaccine (IVV-01), which will be used intra-lesionally.